- Home
- SPRO vs FIRY Comparison
SPRO vs FIRY Comparison
Compare SPRO & FIRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPRO | FIRY |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.3M | 148.6M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SPRO | FIRY |
|---|---|---|
| Price | $2.24 | N/A |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.6M | N/A |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,802,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $300.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $1.80 | N/A |
| 52 Week High | $3.08 | N/A |
Technical Indicators
Market Signals| Indicator | SPRO | FIRY |
|---|---|---|
| Relative Strength Index (RSI) | 42.65 | N/A |
| Support Level | $2.14 | N/A |
| Resistance Level | $2.52 | N/A |
| Average True Range (ATR) | 0.26 | 0.00 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 28.64 | 0.00 |
Price Performance
Historical ComparisonAbout SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.